Interpore Bone Treatment Gets OK
<i> Dow Jones</i>
Interpore Cross International said Tuesday its new bone plate system for treating internal pelvic fractures has been cleared by the Food and Drug Administration. The Irvine medical device company expects the system to be ready for market launch as early as first quarter 1999.
Interpore’s stock was unchanged Tuesday at $4.63.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.